Trial Profile
CRIZOTINIB (XALKORI(REGISTERED)) EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADULT OR PEDIATRIC PATIENTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES THAT HARBOR A CRIZOTINIB-SENSITIVE MOLECULAR ALTERATION BUT WHO ARE UNABLE TO SWALLOW CRIZOTINIB CAPSULES
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
- 29 Feb 2024 Status changed from recruiting to completed.
- 14 Jan 2017 Status changed from suspended to recruiting.
- 18 Jun 2015 New trial record